Global Thrombin Market is anticipated to grow at a higher CAGR
in the forthcoming period. Thrombin is an allosteric enzyme that occurs in dual
forms, slow and fast that vary extensively regarding their specificities
pertaining to synthetic and natural amide substances. Both the forms
importantly account for in vivo state and the allosteric stability can be
disturbed by combining effectors and natural substrates.
Since the fast form can cleave with fibrinogen with higher
specificity due it procoagulant nature. The slow form cleaves with protein C at
a higher specificity due it anticoagulant nature. From the commercial point,
thrombin is a particular enzyme called serine protease, synthesized from a
predecessor glycoprotein named prothrombin. Thrombin is produced naturally in
the body and also available in an artificial form. Artificially prepared
thrombin possesses the ability to convert fibrinogen into fibrin which helps in
formation of thrombus upon the injury site.
Driving factors responsible for the growth of thrombin market includes rise in cases of severe
complications, bleeding due to major injuries and rising prevalence of
hemostasis. Based on segmentation by product, the market includes bovine
thrombin, recombinant thrombin and human thrombin. Human thrombin is further
sub-segmented into alpha, beta gamma thrombin. Based on segmentation by dosage,
the thrombin market includes powder form, pad from, spray kits and solution
form. Segmentation on the basis of end-user for thrombin industry includes
hospitals, diagnostics and clinics, academic and research institutes.
Geographically, thrombin market spans North America, Latin
America, Europe, Asia-Pacific, Middle-East and Africa. North America is
anticipated to lead the global market growth owing to higher cases of surgeries
and better medical infrastructure. APAC and Europe market is expected to gain a
higher CAGR growth owing to rise in population and better medical
infrastructure. MEA regions are also expected to gain a moderate CAGR in the
forthcoming period owing to rise in cases of homeostasis and growing medical
infrastructure. The key players in the thrombin market include Bayer, CSL,
Baxter, CSL, Grifols, GE Healthcare, Hualan Biological, Haematologic
Technologies Inc, Pfizer, Octapharma, Shanghai RAAS and Omrix
Biopharmaceuticals Ltd.
Market
Segment:
Geographically,
this report is segmented into several key Regions, with production,
consumption, revenue (million USD), market share and growth rate of Thrombin in
these regions, from 2012 to 2022 (forecast), covering
• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• North America
• Europe
• China
• Japan
• Southeast Asia
• India
Global
Thrombin market competition by top manufacturers, with production, price,
revenue (value) and market share for each manufacturer; the top players
including
• Baxter
• Bayer
• CSL
• Grifols
• GE Healthcare
• Hualan Biological
• Haematologic Technologies Inc.
• Pfizer
• Octapharma
• Omrix Biopharmaceuticals Ltd.
• Shanghai RAAS
• Baxter
• Bayer
• CSL
• Grifols
• GE Healthcare
• Hualan Biological
• Haematologic Technologies Inc.
• Pfizer
• Octapharma
• Omrix Biopharmaceuticals Ltd.
• Shanghai RAAS
Request Sample Copy of this Market
Research @ https://www.millioninsights.com/industry-reports/thrombin-market/request-sample
Comments
Post a Comment